| Autor: |
Palmarocchi MC; Medical Oncology, Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland., Balzarotti Canger RC; Department of Surgery, Lugano Regional Hospital, 6900 Lugano, Switzerland., Saletti P; Medical Oncology, Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland. |
| Jazyk: |
angličtina |
| Zdroj: |
Oncology letters [Oncol Lett] 2017 Jun; Vol. 13 (6), pp. 4445-4452. Date of Electronic Publication: 2017 Apr 11. |
| DOI: |
10.3892/ol.2017.6026 |
| Abstrakt: |
Pancreatic cancer is the fourth leading cause of cancer mortality and is associated with a poor overall survival even when diagnosed early and considered resectable. Complete surgical removal with negative histological margins is an independent predictor of survival and remains the only potential curative treatment. In borderline resectable pancreatic adenocarcinoma (BRPAC), preoperative systemic therapy may increase resectability and margin-negative resection rate. There is no current consensus on the optimal chemotherapy regimen for BRPAC. The present case describes a patient with BRPAC who achieved a pathological complete response to neoadjuvant FOLFIRINOX (folinic acid, fluorouracil, irinotecan and oxaliplatin), but early relapse following a pancreaticoduodenectomy without vascular resection, with an uneventful postoperative course, except for a pulmonary embolism. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
